*REGENXBIO Q4 LICENSE & ROYALTY REVENUE USD 21.214 MILLION
*REGENXBIO Q4 NET INCOME USD -51.186 MILLION
*REGENXBIO Q4 PRETAX PROFIT USD -51.186 MILLION
*REGENXBIO Q4 OPERATING EXPENSES USD 72.582 MILLION
((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))
Source Date/Time = 13-MAR-202520:05:06.517 GMT